Brokerage Firm Rating on TrovaGene (TROV)

TrovaGene (TROV) : Zacks Investment Research ranks TrovaGene (TROV) as 3, which is a Hold recommendation. 2 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. A total of 1 analysts believe that the stock has a limited upside, hence they advise a Hold. The average broker rating of 3 research analysts is 1.67, which indicates as a Buy.

TrovaGene (TROV) : Currently there are 3 street experts covering TrovaGene (TROV) stock. The most bullish and bearish price target for the stock is $9 and $5 respectively for the short term. The average price target of all the analysts comes to $7. The estimated standard deviation from the target is $2.


Company shares have received an average consensus rating of Hold for the current week TrovaGene (NASDAQ:TROV): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $5.45 and $5.43 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $5.63. The buying momentum continued till the end and the stock did not give up its gains. It closed at $5.57, notching a gain of 2.96% for the day. The total traded volume was 212,238 . The stock had closed at $5.41 on the previous day.

In a related news, Tennant Stanley, director of Trovagene, Inc. had purchased 10,000 shares on August 12, 2015 in a transaction. The price per share was $6.06 and the total amount of the disclosed transaction was $60,600.The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing. This information is based on open market transaction at the market prices.

Trovagene, Inc. is a development-stage molecular diagnostic company that focuses on the development and commercialization of urine-based cell-free molecular diagnostic technology for use in disease detection and monitoring across a variety of medical disciplines. The Companys primary internal focus is to leverage its urine-based molecular diagnostic platform to facilitate improvements in the field of oncology, while its external focus includes entering into collaborations to develop its technology in areas, such as infectious disease, transplant medicine and prenatal genetics. Its cell-free BRAF test confirms the presence of a BRAF V600E mutation in urine DNA at levels of greater than or equal to 0.03% in comparison to the wild-type BRAF genes. Its KRAS mutation assay detects and monitors the seven commonly encountered mutations of the KRAS oncogene. Its urine-based Human Papilloma Virus (HPV) assay identifies women with high grade cervical intraepithelial neoplasia (CIN2/3).

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.